I know this is not the place for investment discussions, but the future of Afrezza is in serious jeopardy with the company's stock dropping below $1 per share, even after a recent reverse split designed to keep the share price above $1 and preserve its NASDAQ exchange listing. The company announced yesterday a restructuring of debt that diluted existing shares, which have hit a new low today of 92 cents. Less than a year ago, the shares were as high as $8.50. The company is strapped for cash, and prescriptions just aren't gaining any traction. The company's in-house marketing efforts, since the distribution deal with Sanofi expired last year, have done nothing to reverse steady sales declines. Unless some type of "white knight" deal develops, Afrezza may not last much longer.